title: [Maxillary T/NK lymphoma. Case report].
abstract: BACKGROUND
  Primary nasal T/NK cell lymphoma is a very rare pathological clinical entity; it was defined by the WHO in 2001, thanks to immunohistochemistry. The treatment combines radiotherapy and chemotherapy. We report a case.
  
  
  METHODS
  A 20-year-old male patient was admitted for ulceration of the vestibular mucosa from tooth 20 to 26, in June 2008. The lesion had appeared four months before, with a painful ulceration close to tooth 25. The lesion evolved progressively, it eroded the alveolar bone, exposing the roots of teeth 24, 25, and 26. CT scan revealed lysis of the external maxillary sinus wall. The diagnosis of T/NK cell lymphoma was obtained by immunohistochemistry of the biopsy. The tumor was staged IeA according to the Ann Arbor classification. After four courses of CHOP chemotherapy and two years of follow-up there was no recurrence.
  
  
  CONCLUSIONS
  Maxillary T/NK cell lymphoma is extremely rare. The diagnosis is based on immunohistochemistry. The treatment associates chemotherapy and radiotherapy. Recent studies suggest that radiotherapy at an early stage could improve the prognosis. But there is no consensus on therapeutic protocols.
authors.affiliation: Service de chirurgie plastique stomatologie et chirurgie maxillofaciale, hôpital militaire d'instruction Mohammed V, Rabat, Maroc. mmoumine@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Moumine
authors.forename: H
authors.initials: H
authors.lastname: Sabani
authors.forename: W
authors.initials: W
authors.lastname: Qamous
authors.forename: M
authors.initials: M
authors.lastname: Nassih
authors.forename: A
authors.initials: A
authors.lastname: Al Bouzidi
authors.forename: A
authors.initials: A
authors.lastname: Rzin
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis*; D008297:Male; D008441:Maxillary Neoplasms / Q000175:diagnosis*; D009367:Neoplasm Staging; D019226:Oral Ulcer / Q000175:diagnosis; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone